Pathology & Oncology Research最新文献

{"title":"Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancers.","authors":"Federico Rossari, Michele Sala, Margherita Rimini, Silvia Camera, Mara Persano, Giovanni Tonon, Chiara Bonini, Maria Giulia Cangi, Lorenza Pecciarini, Claudio Doglioni, Maurilio Ponzoni, Chiara Balestrieri, Federica Pedica, Andrea Casadei-Gardini","doi":"10.3389/pore.2026.1612389","DOIUrl":"10.3389/pore.2026.1612389","url":null,"abstract":"<p><p>Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options. Despite advances with durvalumab plus chemotherapy, prognosis remains poor. The tumor immune microenvironment (TIME) is increasingly recognized as a determinant of immunotherapy response, yet its spatial organization in BTC is poorly understood. We applied multiplex immunofluorescence to pre-treatment tumor samples from 11 patients with advanced BTC, staining for CD4, CD8, CD20, and CD163 to identify T cells, B cells, and macrophages. Across 198 regions of interest sampled at the invasive tumor margin, approximately 400,000 individual cells were segmented and phenotyped. Spatial organization was analyzed using hierarchical clustering, distance-based approaches, and cellular neighborhood classification. Unsupervised analysis identified two distinct immune phenotypes, one enriched in CD4⁺ T cells and CD163⁺ macrophages and the other in CD8⁺ T cells and CD20⁺ B cells. These phenotypes displayed distinct spatial architectures, with CD4⁺ T cells and CD20⁺ B cells acting as organizing hubs, respectively. Targeted sequencing, available for a subset of cases, showed a higher frequency of co-occurring TP53 and ARID1A alterations in the B-cell-enriched phenotype. No statistically significant differences in overall or progression-free survival were observed between immune phenotypes. However, among patients treated with adjuvant cisplatin/gemcitabine alone, lower CD20/CD8 fractions and higher CD163 abundance at baseline were associated with improved survival. Spatial immune profiling revealed distinct BTC immune architectures at the invasive margin, with different possible impact on survival, thus warranting further characterization and validation in larger cohorts.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612389"},"PeriodicalIF":2.7,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13253487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148252822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotyping of suspected partial hydatidiform moles - our experiences and future directions.","authors":"Lajos Gergely, Vanda Repiska, Juraj Hutnik, Natalia Andova, Lubica Milosovicova, Miroslav Korbel, Liam McCullough, Alexandra Kristufkova, Ludovit Danihel, Helena Gbelcova, Petra Priscakova","doi":"10.3389/pore.2026.1612410","DOIUrl":"10.3389/pore.2026.1612410","url":null,"abstract":"<p><p>This brief research report summarizes our experience with the molecular differential diagnosis of clinically or pathologically suspected partial hydatidiform moles and discusses practical diagnostic options when economic resources or laboratory infrastructure are limited. We analyzed the genome composition of 68 suspected cases using short tandem repeat genotyping based on quantitative fluorescent PCR and fragmentation analysis. Genetic testing excluded a partial mole in 35 cases (51%) by demonstrating a diploid or monogynic monoandric diploid genome, while in 33 cases (49%) a partial mole was confirmed through identification of diandric triploidy (31 cases) or triandric tetraploidy (2 cases). No instances of digynic triploidy were detected in this cohort. Our findings indicate that, in the absence of access to a DNA laboratory, most suspected partial moles can still be accurately evaluated using ploidy assessment by more widely available methods, such as fluorescent <i>in situ</i> hybridization, DNA flow cytometry, or conventional karyotyping, given the apparent rarity of digynic triploidy among these cases.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612410"},"PeriodicalIF":2.7,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13243142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148212166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of p53 and HER2 immunohistochemistry profiles in colorectal carcinoma.","authors":"Michal Grus, Hana Fišerová, Karolína Jelínková, Andrej Nikov, Radoslav Matěj, Petr Waldauf, Jan Hrudka","doi":"10.3389/pore.2026.1612343","DOIUrl":"10.3389/pore.2026.1612343","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a significant health issue worldwide, but represents biologically heterogeneous disease, necessitating improved characterization of molecular and immunophenotypic subgroups. In this retrospective study, we evaluated the prognostic significance and clinicopathological associations of p53 and HER2 expression in 290 surgically resected CRCs. Tissue microarrays from archival formalin-fixed paraffin-embedded samples were analyzed by immunohistochemistry. p53 expression was categorized into wild-type, overexpression, and null patterns, while HER2 was scored according to College of American Pathologists criteria used for gastric carcinoma. Survival analyses were performed using Kaplan-Meier estimates, univariable and multivariable Cox regression, and restricted mean survival time, and immunohistochemical results were correlated with established clinicopathological and molecular features. Neither aberrant p53 expression nor HER2 positivity had a significant impact on 10-year overall survival. The p53 null phenotype showed a significantly increased relative risk of death within 5 years and a significant adverse effect in multivariable Cox regression of 5-year survival adjusted for age. Aberrant p53 expression was significantly associated with left-sided tumor location, mismatch repair proficiency, CK20 positivity, and MUC6 negativity, consistent with the chromosomal instability pathway of CRC. HER2 expression was infrequent and showed no prognostic relevance; however, HER2-positive tumors were significantly associated with CK7 expression, supporting an \"extraintestinal\" immunophenotypic profile reminiscent of right-sided or non-intestinal differentiation. In conclusion, while p53 and HER2 expression lacked independent prognostic value, their distinct associations with tumor phenotype underscore biologically relevant CRC subgroups.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612343"},"PeriodicalIF":2.7,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed diagnostic imaging but stable treatment initiation for kidney cancer during the COVID-19 pandemic: a Hungarian cohort study.","authors":"László Rumi, Árpád Szántó, Dániel Bányai, Éva Szabó, Szabolcs Bellyei, Dóra Hubai, Balázs Takáts, Tamás Bodnár, János Girán, István Kiss, Árpád Boronkai, Éva Pozsgai","doi":"10.3389/pore.2026.1612411","DOIUrl":"10.3389/pore.2026.1612411","url":null,"abstract":"<p><strong>Background/objectives: </strong>The COVID-19 pandemic influenced cancer care worldwide, delaying diagnosis and treatment. We compared waiting times - time to initial diagnostic imaging, time to treatment, time to histopathological diagnosis, and length of hospital stay - of kidney cancer patients between pre-COVID-19 and COVID-19 periods at a large regional Hungarian clinical center. We also aimed to identify factors predicting prolonged waiting times.</p><p><strong>Methods: </strong>Data from 400 adult kidney cancer patients (all histologically renal cell carcinoma) at the University of Pécs Urology Clinic were analyzed retrospectively, for two periods (1 January 2019-15 March 2020, pre-pandemic; 16 March 2020-13 May 2021, pandemic). Demographic and clinical characteristics were collected, and time intervals calculated from electronic health records, followed by statistical analyses.</p><p><strong>Results: </strong>Median time from symptom onset to initial diagnostic imaging increased significantly from 7.5 to 34 days during the pandemic (p = 0.026), while time to treatment (p = 0.492), time to histopathological diagnosis (p = 0.575), and length of hospital stay (p = 0.319) remained stable. Median healthcare-related waiting times (time to treatment and time to histopathological diagnosis) were comparatively long (range: 95.5-111 days). Advanced-stage disease (III-IV) was protective for prolonged time to initial diagnostic imaging (OR 0.205, 95% CI 0.074-0.568) pre-pandemic and for prolonged time to histopathological diagnosis (OR 0.496, 95% CI 0.254-0.971) during the pandemic. No other demographic or clinical factors influenced waiting times significantly.</p><p><strong>Conclusion: </strong>The pandemic prolonged the interval from symptom onset to initial diagnostic testing, likely due to fear-driven healthcare avoidance by patients, but did not affect healthcare-related waiting times. Advanced-stage disease predicted shorter waiting times, with variable influence across periods. Our findings highlight the need for patient education and careful prioritization of care, with waiting times exceeding those reported in other international settings.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612411"},"PeriodicalIF":2.7,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13212254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148056205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic resonance imaging based radiomics for predicting pathogenetic features and survival in rectal cancer.","authors":"Bertalan Toth, Marcell Mesterházi, Istvan Szabo, Tamas Mersich, Erika Toth, Janos Szoke, Andras Benczur, Csaba Kerepesi, David Laszlo Tarnoki, Adam Domonkos Tarnoki","doi":"10.3389/pore.2026.1612303","DOIUrl":"10.3389/pore.2026.1612303","url":null,"abstract":"<p><strong>Background: </strong>Prediction of pathologic features and outcome in patients with rectal cancer is challenging as a result of lack of a significant biomarker and heterogeneity between and within tumors. This study aims to evaluate the potential of Magnetic Resonance Imaging (MRI)-based radiomics in predicting key pathological features and long-term survival outcomes in patients.</p><p><strong>Methods: </strong>A retrospective study was conducted on 510 rectal cancer patients treated between 2015 and 2019. The inclusion criteria required pre-therapeutic MRI performed on a Discovery MR750W 3.0T machine and known KRAS mutation status. Forty-seven patients met the criteria. MRI sequences included T1-weighted, T2-weighted fat-saturated (T2FS), high-resolution T2-weighted (T2HR), and diffusion-weighted imaging (DWI). Radiomic features were extracted using PyRadiomics, and machine learning models were developed using XGBoost and LightGBM classifiers. Feature selection was performed using Sequential Feature Selector (SFS) and Minimum Redundancy Feature Selection (mRMR).</p><p><strong>Results: </strong>The model for KRAS mutation status achieved an Area Under the ROC curve (AUC) of 0.7475 (training) and 0.75 (testing). Lymph node invasion prediction had an AUC of 0.7892 (training) and 0.7984 (testing). Vascular invasion prediction yielded an AUC of 0.6989 (training) and 0.7143 (testing). The 5-year survival prediction model showed an AUC of 0.7848 (training) and 0.7750 (testing). Metastasis prediction achieved an AUC of 0.6627 (training) and 0.6857 (testing).</p><p><strong>Conclusion: </strong>MRI-based radiomics demonstrates significant potential in predicting key pathological features and long-term survival outcomes in rectal cancer patients. Integrating multimodal imaging data and clinical information, along with automated segmentation techniques, could further enhance model accuracy and clinical utility.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612303"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13189980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148016833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postpartum acquired hemophilia A: immunopathogenesis, diagnostic challenges, and treatment with the CyDRi protocol.","authors":"Ágnes Szappanos, Hajnalka Andrikovics, Péter Varga, Mónika Fekete, Vince Fazekas-Pongor, Márk Lehoczki, Viktória Király, Beáta Vilimi, Gábor Mikala, Imre Bodó, Andrea Ceglédi","doi":"10.3389/pore.2026.1612302","DOIUrl":"10.3389/pore.2026.1612302","url":null,"abstract":"<p><p>Acquired hemophilia A (AHA) is a rare, potentially life-threatening autoimmune bleeding disorder characterized by the development of inhibitory autoantibodies against factor VIII (FVIII). While most commonly diagnosed in the elderly, AHA can also occur in the postpartum period, where it presents unique diagnostic and therapeutic challenges. This review provides a comprehensive overview of the pathogenesis, clinical features, diagnostic approaches, and current therapeutic strategies for postpartum AHA. We highlight the immunological shifts during pregnancy and the postpartum period that may contribute to the breakdown of immune tolerance and the emergence of FVIII autoantibodies. Key aspects of laboratory diagnosis are outlined, including the role of coagulation screening, mixing studies, and inhibitor assays. We compare the efficacy and safety of established immunosuppressive regimens, with a particular focus on the CyDRi protocol-a combination of cyclophosphamide, dexamethasone, and rituximab-which has demonstrated high rates of complete remission with a favorable toxicity profile. To illustrate clinical application, we describe a case of severe postpartum AHA managed successfully with the CyDRi protocol, followed by an uneventful subsequent pregnancy. With timely diagnosis and appropriately tailored immunosuppressive therapy, postpartum AHA can be effectively treated, and favorable hematologic and reproductive outcomes are achievable.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612302"},"PeriodicalIF":2.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13180712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147974520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: The molecular profile of granular cell astrocytoma predicts aggressive clinical behavior, independent of morphology.","authors":"Melanie Jensen, Pranoy Das, Oliver Wroe-Wright, Oscar MacCormac, Francesco Marchi, Ali Elhag, Yasir A Chowdhury, Ross Laxton, Rebecca Ellmers, Omar Al-Salihi, Keyoumars Ashkan, Ranjeev Bhangoo, Francesco Vergani, Istvan Bodi, Zita Reisz, Jose Pedro Lavrador","doi":"10.3389/pore.2026.1612388","DOIUrl":"10.3389/pore.2026.1612388","url":null,"abstract":"<p><strong>Background: </strong>Granular cell astrocytoma (GCA) is a rare, morphologically distinct variant of IDH-wildtype glioblastoma that can appear deceptively low-grade yet behave aggressively. Its molecular features remain poorly defined, and no methylation-based classification has previously been reported.</p><p><strong>Methods: </strong>Two GCAs diagnosed in our clinical neuropathology department were described with the integration of clinical, intraoperative, histopathological, and molecular data, including DNA methylation profiling, a targeted next-generation sequencing panel, and, in one case, whole genome sequencing (WGS).</p><p><strong>Results: </strong>The patients were aged 63 and 54 years old, respectively, both presenting with supratentorial tumors showing granular cell morphology. Case 1 showed a densely cellular tumor composed entirely of bland-appearing granular cells without a conventional astrocytic component. Case 2 showed low-grade granular cell areas transitioning into high-grade astrocytic regions with mitoses, microvascular proliferation, and necrosis. Despite these morphological differences, both cases matched the methylation class \"Glioblastoma, IDH-wildtype, mesenchymal subtype\" and shared molecular features typical of glioblastoma, including chromosome +7/-10 and <i>CDKN2A/B</i> deletion. Both patients harbored oncogenic <i>NF1</i> variants. WGS in Case 2 also revealed homozygous <i>MTAP</i> loss and chromoanasynthesis on chromosome 9. Case 1 received Stupp protocol chemoradiotherapy, recurred after 3 months of treatment, and died 11 months after diagnosis. Case 2 has progressed with a new posterior fossa lesion while on adjuvant temozolomide.</p><p><strong>Conclusion: </strong>These cases demonstrate that GCAs span a morphological spectrum yet molecularly correspond to the mesenchymal subtype of IDH-wildtype glioblastoma. Integrated molecular testing is therefore essential for accurate diagnosis and for guiding clinical management, including consideration for potential clinical trial enrollment.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612388"},"PeriodicalIF":2.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13180715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147974563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal prehabilitation for upper gastrointestinal tumors: effects on postoperative morbidity and mortality - a meta-analysis of randomized controlled trials.","authors":"Csenge Papp, Armand Csontos, Daniel Kehl, Lili Dora Sindler, Andras Vereczkei, Andras Papp","doi":"10.3389/pore.2026.1612328","DOIUrl":"10.3389/pore.2026.1612328","url":null,"abstract":"<p><strong>Background: </strong>Patients suffering from upper gastrointestinal (UGI) cancers often present with malnutrition and frailty before undergoing major surgical procedures, which significantly elevates the risk of postoperative complications. Prehabilitation focuses on optimizing a patient's functional capacity before surgery to improve postoperative outcomes. Our goal was to synthesize the effects of prehabilitation on the postoperative outcomes of UGI cancer patients undergoing major surgical intervention using a systematic review and meta-analysis.</p><p><strong>Methods: </strong>A comprehensive systematic search was conducted across the PubMed, Embase, Cochrane, and Scopus databases to identify relevant randomized controlled trials (RCTs). Ten RCTs, encompassing data from 878 patients, were included in the analysis. Pooled risk ratios (RRs) were calculated for dichotomous variables (e.g., incidence of complications), and weighted mean differences were calculated for continuous variables using a random-effects model. Study quality was assessed using the RoB2 and GRADE approaches.</p><p><strong>Results: </strong>The meta-analysis showed a trend toward a lower incidence of minor postoperative complications (Clavien-Dindo Grade I-II) in the prehabilitation group. While the common effect model showed significance, the certainty of evidence remains low to very low for most outcomes, suggesting these results should be interpreted with caution. However, a significant reduction was found in Grade III complications when using a common effect model, although no significant differences were detected in Grade IV complications or mortality. Cardiovascular complications and hospital readmission rates also showed no significant disparity.</p><p><strong>Conclusion: </strong>The implementation of prehabilitation in UGI cancer patients is safe and shows a positive trend toward reducing minor postoperative complications, thereby enhancing patient comfort and potentially accelerating recovery time. While the certainty of evidence remains low, further high-quality RCTs with larger patient cohorts are warranted, especially to explore the role of multimodal prehabilitation.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612328"},"PeriodicalIF":2.7,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13160875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147932522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical management of ulcerative colitis-associated colorectal cancer in a 20-year period, a single-centre study.","authors":"János Tajti, László Libor, Szabolcs Ábrahám, Zsolt Simonka, Anikó Maráz, Attila Paszt, Tamás Molnár, Judit Oláh, György Lázár","doi":"10.3389/pore.2026.1612362","DOIUrl":"10.3389/pore.2026.1612362","url":null,"abstract":"<p><strong>Introduction: </strong>The incidence of inflammatory bowel disease is on the rise. Inflammation that persists for years or decades may involve the risk of malignant transformation. Indeed, it is the cause of death in 15% of the UC patient population. Proctocolectomy followed by ileal pouch-anal anastomosis is the accepted surgical procedure.</p><p><strong>Aim: </strong>Our study objective was to retrospectively assess the occurrence and surgical treatment of UC-associated colorectal cancer cases in our institute and analyse survival data.</p><p><strong>Materials and methods: </strong>In our department, 39 patients (12 female and 27 male patients) underwent surgery for UC-associated colorectal cancer between 1 January 2005 and 1 January 2025. Their mean age was 55 ± 13.4 years. Risk factors for the disease, examination results, types of surgery, perioperative and long-term surgical results, and survival measures were assessed retrospectively. The latter were determined using the Kaplan-Meier analysis.</p><p><strong>Results: </strong>Thirty-nine patients were diagnosed with UC at a mean age of 35.7 ± 16.7 years, and an average of 19.4 ± 12.3 years passed between the diagnosis of UC and the first surgical intervention. Regular endoscopies were performed in only 66% of our patients. Preoperative staging confirmed distant metastases in 12 patients (30.7%). Patients underwent 34 elective and 5 emergency surgeries. The mean follow-up duration was 40.2 ± 51.7 months. Only 7 patients (17.9%) had a T1 lesion. Lymph node involvement was confirmed in 17 cases (44.5%), whereas 12 patients (30.7%) showed dissemination. Adjuvant chemotherapy was administered in 23 cases (58.9%), and follow-up was recommended for 13 patients (33.3%). During the study period, 17 of the 39 patients died. The mean survival after the surgical procedure was 98.6 months (8.2 years). Survival was significantly shorter in patients who had undergone emergency surgery, were active smokers, suffered from PSC, and lacked gastroenterological follow-up.</p><p><strong>Conclusion: </strong>Based on our experience, it is especially important for UC patients to receive close gastroenterological follow-up in specialised centres and undergo regular colonoscopies and for staff to evaluate biopsy samples properly and perform the appropriate surgical procedures in due time, preferably proctocolectomy and creation of IPAA with a minimally invasive method.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612362"},"PeriodicalIF":2.7,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Thigh anastomotic hemangioma.","authors":"Li Chen, Xia Gao, Qiang Zhang","doi":"10.3389/pore.2026.1612402","DOIUrl":"10.3389/pore.2026.1612402","url":null,"abstract":"<p><p>Anastomotic hemangioma (AH) is a rare benign vascular tumor primarily occurring in the genitourinary tract; however, only two cases have been reported in the thigh. In this report, a 42-year-old female patient presented to the hospital for examination due to \"a subcutaneous mass on the lateral aspect of the left thigh discovered 9 months ago, which has been gradually enlarging.\" Subsequently, the lump was removed via local surgery. Histological examination reveals: At low magnification, the tumor was situated within the superficial subcutaneous fascia layer, presenting a loose lobular structure. Most of its margins were well - defined, while a small portion displayed expansile infiltrative changes. There were well - differentiated vascular lumens arranged in a communicating or anastomosing pattern, along with pseudopapillary structures. At high magnification, tumor cells were oval or short spindle - shaped, with vacuoles in the cytoplasm that contain red blood cells or homogeneously red - stained glassy globules. Moderate atypia was present, and mitotic activity was frequent, with hot spots averaging approximately 4/mm². PCR-<i>GNAQ</i> mutation detection result: detected a missense mutation at codon 209 in exon 5 (<i>c.627A>T, p. Q209H</i>). Follow-up revealed tumor recurrence 10 months after surgery. Given the rarity of AH occurring on skin surfaces, coupled with the high proliferative activity observed in this case and its recurrence following excision, we report the diagnostic and therapeutic process along with the clinical and pathological features of this AH case. This aims to enhance the understanding of this disease among clinicians and pathologists.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612402"},"PeriodicalIF":2.7,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147778263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}